BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort- Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- Journalists killed by Israeli strike in southern Lebanon
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- Excited visitors for NASA's moon launch jockey for prime views
- 'People We Meet on Vacation' is the 1st of many Emily Henry adaptations: What other books turned movies to look forward to
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
